Search Results

Attention Hodgkin Lymphoma Patients and Caregivers!

Lymphoma patient and family give back

Edward Jones & The Leukemia & Lymphoma Society

Diffuse Large B-Cell Lymphoma (DLBCL)

How is Mantle Cell Lymphoma Treated?

Research Accelerator for Follicular Lymphoma I (RAFL-I)

Non-Hodgkin Lymphoma 3D Model

.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }

This model contains the following chapters. Click the "Interact in 3D" button to begin.

• Healthy Bone Marrow
• Normal Blood Cell Production
• Proliferation of Cells and the Crowding Out of Normal Cells
• Signs and Symptoms

Rituximab and hyaluronidase human

Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:

Diagnosed with a Blood Cancer? Important Questions You Might Not Think to Ask

What is my actual diagnosis? Find out your exact diagnosis. Ask your doctor to write down the exact name of your sub-type and take the paper with you. For example, knowing you have “a B-cell lymphoma” isn’t good enough. Follicular and diffuse large B-cell are both B-cell lymphomas but with very different prognoses and treatment plans. Leukemia also has different sub-types. Knowing your specific sub-type helps you understand what disease you are dealing with, how aggressive it is, and what to expect from treatment.

Insurance Inequities in Hodgkin Lymphoma Treatment and Survivorship in the Southeast

Black and Hispanic individuals diagnosed with Hodgkin lymphoma (HL) face worse survival rates across all ages. Using an innovative data source, this study will examine differences by insurance status in the receipt and quality of HL treatment in Aim 1 and care engagement and support after treatment (survivorship care) in Aim 2. Using diverse patient voices, this study will characterize and understand how patients make decisions about treatment and survivorship care by insurance type in Aim 3.

Tisagenlecleucel

Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of

Exploiting escape from Y-inactivation as a synthetic dependency in MYC-driven lymphoma

As a lymphoma develops it expresses genes that are normally silenced to convey a survival advantage. When these genes are on the X or Y (sex chromosomes) they may present a gender-specific therapeutic target. We have identified a gene (DDX3X in females or DDX3Y in males) that is reactivated in lymphomas such that the lymphomas cannot survive if this gene is removed. This project will develop new ways to inhibit DDX3X and Y as a novel treatment for poor-risk and aggressive lymphoma.

Loncastuximab

Loncastuximab tesirine-lpyl is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma. 

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 

Pralatrexate

Pralatrexate is FDA approved to treat people who have relapsed or refractory peripheral T-cell lymphoma. It is being studied to treat people who have other forms of lymphoma including diffuse large B-cell lymphoma.

Investigating the role of CREBBP mutations and epigenetic crosstalk in B-cell lymphoma

We seek to understand the genetic and epigenetic etiology of B-cell lymphoma and how deregulation of normal epigenetic programs perturb developmental programs and immune interactions. We approach this using a variety of genomic technologies to interrogate primary human tumors, CRISPR-engineered cell lines, patient-derived xenograft models and transgenic mouse models with different genetic lesions.

The Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma

Cellular and genetic drivers of Cutaneous γδ T-cell lymphomas (PCGDTL)

Primary cutaneous γδ T-cell lymphoma (PCGDTL) is a rare type of lymphoma caused by the rare types of T-cells called γδ T-cells (most T cells in our body in αβ T-cells). The disease usually shows symptoms in the skin, thus it is also considered a rare type of skin cancer. The disease is very aggressive. After diagnosis patients may die within 3 months. Only about 10% patients are alive after 5 years. However, little is known about the disease. For the last two decades, most knowledge has been generated with a handful of patient samples.

Blood Cancer Research Poised for Another ‘Banner Year’ in 2024

More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.   

Translating molecular profiles into treatment approaches to target disparities in lymphoma

Although many patients with diffuse large B-cell lymphoma (DLBCL) are cured with standard therapy, others will die from their disease. Survival is significantly worse for African American (AA) patients and those with Epstein- Barr virus (EBV), which is common in patients from Latin America. The reasons behind these poor outcomes are not well understood, in part because most studies of molecular features in lymphomas have not included enough patients from these racial and ethnic groups.

Glofitamab-gxbm

Glofitamab-gxbm is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. 

Zanubrutinib

Zanubrutinib is indicated for the treatment of adult patients with:

Tazemetostat

Tazemetostat is a methyltransferase inhibitor indicated for the treatment of:

Relevance of ubiquitin dependent proteolysis in Diffuse Large B-cell lymphoma

The goal of this proposal is to investigate the significance of genes of the ubiquitin proteasome system (UPS) that are mutated in Diffuse Large B-cell Lymphoma (DLBCL). Our studies leverage the expertise in the molecular modeling of the UPS in the pathogenesis of DLBCL utilizing mouse models, patient derived xenotransplant (PDX) and cell lines. Our goal is the understanding of how genetic mutations contribute to disease development, progression and therapeutic outcome.

Meet The Researcher: Dr. Christopher R. Flowers